Volume 12, Issue 2, March 2018



Opportunities and challenges in oncology and molecular testing: the Belgian strategy

A. Hébrant, E. Van Valckenborgh, R. Salgado, G. Froyen, F. Hulstaert, D. Roberfroid, S. Tejpar, A. Jouret-Mourin, M. Van den Bulcke, A. Waeytens

Prevention of chemotherapy-induced nausea and vomiting: Belgian antiemetic treatment options anno 2018

W. Lybaert, P. Clement, K. Punie, J. Mebis, M. Renard, H. Wildiers

Second-line treatment of non-small cell lung cancer adenocarcinoma patients not harbouring an oncogene driver mutation anno 2017–2018: A consensus group meeting

P-E. Baugnée, L. Bosquée, C. Compère, N. D’Haene, I. Demedts, D. Galdermans, P. Germonpré, M. Gustin, V. Ninane, S. Ocak, P. Pauwels, T. Pieters, A. Sadowska, A. Sibille, V. Surmont, J. Vansteenkiste


Primary leiomyosarcoma of the thyroid: case report and review of the literature

E. Verhelst, S. De Schepper, S. Declercq, D. Schrijvers


Exploring extracellular vesicles for siRNA delivery and Raman-based diagnostics

S. Stremersch, S. De Smedt, K. Braeckmans, K. Raemdonck


Highlights of Scientific Summits Meeting

M. Waterschoot, B. Hermans, M. Claessens, K. Decaestecker, G. De Meerleer, L. Goeman, S. Joniau


New oncology reimbursements in Belgium

P. Specenier